Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

In vivo Screening Methods Targeting Levels of Tau Protein within Mouse Brains

Award Number: R21AG088501
ORGANIZATION: NATIONAL INSTITUTE ON AGING
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 08/01/2024
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

In vivo Screening Methods Targeting Levels of Tau Protein within Mouse Brains - PROJECT SUMMARY/ABSTRACT Neurodegenerative diseases are devastating, fatal diseases that affect millions of people worldwide and have no definitive treatment. A well-known neurodegenerative disease, Alzheimer's Disease (AD), is the third most common leading cause of death, with the AD Association in 2022 reporting more than 6 million people affected in US. Although there are no clear underlying mechanisms of pathogenesis, accumulation of toxic protein species, such as tau protein in AD, drives a large and diverse group of neurodegenerative diseases, both genetic and sporadic. Modulating levels of disease-driving proteins has improved disease phenotypes, highlighting a promising strategy for therapeutic development. Large-scale cell-based genetic perturbation screens are canonical and critical tools used to find essential protein regulators that control levels of disease- driving proteins. However, since these 2D models consist of actively dividing cells with vastly different properties that lack physiological authenticity compared to in vivo cells, important brain-specific regulators are not present and thus not detected and false positives are more likely to be detected. This results in an inefficient process requiring multiple rounds of labor-intensive in vitro assays followed by validation using in vivo models before animal studies can be performed that will hopefully lead to valid therapeutic targets. The goal of this proposal is to bypass cell-based screens by developing a feasible and high- throughput genome-wide in vivo CRISPR/Cas9 screening method (Aim 1). Furthermore, to enhance translation and as a means of validation, this method will be used to find regulators of tau protein levels in the mouse brain (Aim 2). Aim 1 will set the parameters for in vivo screening using intracerebroventricular (ICV) injection of the adeno-associated virus (AAV) harboring gRNA/Cas9 into neonatal mice to broadly perturb target genes in the brain. Fluorescence activated cell sorting (FACS) analysis will then be utilized to track protein levels in each dissociated single cell in a high throughput manner. Aim 2 will expand the in vivo screening method into a tauopathy mouse model, which recapitulates AD-related phenotypes and involves the pathogenic accumulation of tau protein in two brain regions (cerebral cortex and striatum) vulnerable to neurodegeneration. The impact of this proposal is manifold: providing a powerful tool to bypass labor-intensive in vitro processes for the identification of new therapeutic targets for numerous neurodegenerative diseases; providing comprehensive insight into the regulation of tau and reveal candidate therapeutic targets for tauopathies; enhancing our understanding of how disease-causing proteins are differently regulated depending on the brain region, in normal physiological conditions versus disease condition, which will provide insight into regional vulnerability/resilience to neurodegeneration. Taken together, completion of this endeavor will provide a novel and powerful tool to understand the regulation of disease-driving proteins and will help us discover promising therapeutic targets that are validated in the brain, making the strategy applicable to many neurological diseases.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Aging Research	000	2	3/31/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $280,875 )
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Aging Research	000	2	3/31/2025	NON-COMPETING CONTINUATION	$252,788
2025	2025	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Aging Research	001	2	4/28/2025	NON-COMPETING CONTINUATION	$28,087
														Subtotal = $280,875

Issue Date FY: 2024 ( Subtotal = $160,500 )
2024	2024	BAYLOR COLLEGE OF MEDICINE	1 BAYLOR PLZ	HOUSTON	TX	77030	HARRIS	USA	Aging Research	000	1	7/18/2024	NEW	$160,500
														Subtotal = $160,500

Grand Total All Awards = $441,375

Top

All Categories

About

Search

Reports

Data Submission

Award Information

In vivo Screening Methods Targeting Levels of Tau Protein within Mouse Brains

Award Number: R21AG088501

ORGANIZATION: NATIONAL INSTITUTE ON AGING

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 08/01/2024

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer